Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02XYA
|
|||
| Former ID |
DNCL002769
|
|||
| Drug Name |
Astuprotimut-R
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y] | Phase 3 | [1] | |
| Company |
GlaxoSmithKline
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Melanoma-associated antigen 3 (MAGEA3) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00796445) A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor. U.S. National Institutes of Health. | |||
| REF 2 | National Cancer Institute Drug Dictionary (drug id 600553). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.